HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment. Comet Study Group.
Neumann, A U
HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment. Comet Study Group. [electronic resource] - AIDS (London, England) Apr 1999 - 677-83 p. digital
Publication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
0269-9370
10.1097/00002030-199904160-00008 doi
Anti-HIV Agents--administration & dosage
CD4 Lymphocyte Count
Drug Administration Schedule
Drug Therapy, Combination
HIV Infections--drug therapy
HIV Protease Inhibitors--therapeutic use
HIV-1--physiology
Humans
Indinavir--therapeutic use
Lamivudine--therapeutic use
Male
Prospective Studies
RNA, Viral--blood
Reverse Transcriptase Inhibitors--therapeutic use
Zidovudine--therapeutic use
HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment. Comet Study Group. [electronic resource] - AIDS (London, England) Apr 1999 - 677-83 p. digital
Publication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
0269-9370
10.1097/00002030-199904160-00008 doi
Anti-HIV Agents--administration & dosage
CD4 Lymphocyte Count
Drug Administration Schedule
Drug Therapy, Combination
HIV Infections--drug therapy
HIV Protease Inhibitors--therapeutic use
HIV-1--physiology
Humans
Indinavir--therapeutic use
Lamivudine--therapeutic use
Male
Prospective Studies
RNA, Viral--blood
Reverse Transcriptase Inhibitors--therapeutic use
Zidovudine--therapeutic use